Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet
In CARES 310, camrelizumab plus rivoceranib demonstrated statistically significant and clinically meaningful prolonged overall survival and progression-free survival, and improved overall response rate versus sorafenib, a standard first-line treatment for uHCC Fort Lee, New Jersey, July 24, 2023 – Elevar Therapeutics, Inc., a majority-owned subsidiary of
